<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Ev3 Incorporated</title>
	<atom:link href="http://www.stockbloghub.com/tag/ev3-incorporated/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(CSII) Cardiovascular Systems&#8217; Portfolio Gets Expanded in Marketing Agreement</title>
		<link>http://www.stockbloghub.com/2009/08/28/csii-cardiovascular-systems-portfolio-gets-expanded-in-marketing-agreement/13804</link>
		<comments>http://www.stockbloghub.com/2009/08/28/csii-cardiovascular-systems-portfolio-gets-expanded-in-marketing-agreement/13804#comments</comments>
		<pubDate>Fri, 28 Aug 2009 22:59:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cardiovascular Systems Incorporated]]></category>
		<category><![CDATA[CSII]]></category>
		<category><![CDATA[Ev3 Incorporated]]></category>
		<category><![CDATA[EVVV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13804</guid>
		<description><![CDATA[Yesterday, Cardiovascular Systems Inc. (CSII) announced that it has agreed to market Japan-based Asahi Intecc Co. Ltd’s peripheral guide wire line in the United States. The peripheral guide wires address long, complex lesions above or below the knee, and complement the plaque removal capabilities of Cardiovascular’s main product, the Diamondback 360. The company intends to offer two Asahi 0.18 wire platforms; the Astato 30 and Treasure 12. This agreement not only expands Cardiovascular’s product portfolio but also consolidates its top position in the peripheral arterial disease (PAD) market. This agreement is in tune with the company’s mission to provide in excess of 5,000 physicians and 2,000 hospitals treating PAD with comprehensive endovascular tools. The Diamondback 360 Orbital Atherectomy System is a minimally invasive catheter system used for PAD treatment. PAD ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/28/csii-cardiovascular-systems-portfolio-gets-expanded-in-marketing-agreement/13804/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CSII) Cardiovascular Systems Better Than Expected Results</title>
		<link>http://www.stockbloghub.com/2009/08/20/cardiovascular-systems-better-than-expected-results/12916</link>
		<comments>http://www.stockbloghub.com/2009/08/20/cardiovascular-systems-better-than-expected-results/12916#comments</comments>
		<pubDate>Thu, 20 Aug 2009 18:51:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cardiovascular Systems Incorporated]]></category>
		<category><![CDATA[CSII]]></category>
		<category><![CDATA[Ev3 Incorporated]]></category>
		<category><![CDATA[EVVV]]></category>
		<category><![CDATA[Spectranetics Corporation]]></category>
		<category><![CDATA[SPNC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12916</guid>
		<description><![CDATA[Cardiovascular Systems, Inc. (CSII) reported better-than-expected results for the fourth quarter of fiscal 2009. For the quarter, its loss per share was 40 cents, better than the Zacks Consensus Estimate of 58 cents and the year-ago loss per share of $2.34. Quarterly results Sales Net sales in the quarter increased roughly 59% year over year to $15.7 million. Growth was primarily due to increased adoption of company product the Diamondback 3600.  The number of hospitals using the Diamondback 3600 was 556, compared to 183 at the end of the year-ago quarter. Higher sales of disposable devices also contributed to the total growth in net sales. The number of disposable devices sold in the quarter was 4,700 units, compared to 3,000 units in the year-ago quarter. Margins Gross margin increased 1,020 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/20/cardiovascular-systems-better-than-expected-results/12916/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

